PharmaLeaders.com

News. Resources. Community.

Helperby Therapeutics’ combination antibiotic therapy is effective against WHO critical priority pathogen in phase 1 study

by

Published 20 April 2018 Helperby Therapeutics has announced Phase I results on the tolerability, pharmacokinetics, pharmacodynamics and efficacy of AZT and colistin both alone and as a combined therapy, against multi-drug resistant Enterobacteriaceae (CRE), one of the most serious drug resistant pathogens. Helperby also presented preclinical data which shows that AZT is active … [Read more...]

Shire rejects $63bn takeover proposal from Takeda

by

PBR Staff Writer Published 20 April 2018 Ireland-based Shire has rejected a $63bn acquisition offer from Takeda Pharmaceutical, saying that it undervalues the company, its growth prospects and pipeline. The rare disease drug maker revealed that the Japanese pharma company made three offers recently. Takeda’s latest offer came on 13 April, which was £46.50 per each … [Read more...]

BenevolentAI raises $115m to advance AI-enabled drug development activities

by

PBR Staff Writer Published 19 April 2018 BenevolentAI has secured $115m funding to advance drug development activities and extend its artificial intelligence (AI) platform capabilities. The company has raised the funding from new and existing investors at a pre-money valuation of $2bn in the financing round of the AI pharmaceutical sector. From 2013, BenevolentAI has … [Read more...]

FDA approves Tagrisso as first-line treatment for EGFR-mutated non-small cell lung cancer

by

Published 19 April 2018 The US Food and Drug Administration (FDA) has approved AstraZeneca’s Tagrisso (osimertinib) as the first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations. The approval is based on results from the Phase III FLAURA trial, which were presented at the … [Read more...]